Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depo Provera. Position paper on clinical use, effectiveness and side effects.

A Bigrigg, M Evans, B Gbolade

    The British Journal of Family Planning
    |August 24, 1999
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Discussion.

    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2017
    Same author

    Comparing the performance of six human papillomavirus tests in a screening population.

    British journal of cancer·2013
    Same author

    Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

    International journal of cancer·2011
    Same author

    HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial.

    British journal of cancer·2011
    Same author

    Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study.

    British journal of cancer·2010
    Same author

    Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

    Lancet (London, England)·2009

    Depo Provera (medroxyprogesterone acetate) is a highly effective, long-acting reversible contraceptive. Proper patient counseling is crucial to manage potential side effects like menstrual changes and weight gain.

    Area of Science:

    • Reproductive Health
    • Pharmacology
    • Contraception

    Background:

    • Depo Provera (medroxyprogesterone acetate, DMPA) is a highly effective injectable contraceptive.
    • Its efficacy is comparable to modern copper IUDs and superior to many other reversible methods.
    • DMPA offers an advantage due to its independence from intercourse and user memory, unlike daily oral contraceptives.

    Purpose of the Study:

    • To evaluate the effectiveness and suitability of DMPA as a first-line reversible contraceptive method.
    • To highlight the importance of pre-use counseling for managing potential side effects.
    • To compare DMPA with other contraceptive methods, including oral contraceptives and IUDs.

    Main Methods:

    • Review of DMPA's pharmacological profile and clinical effectiveness.
    Keywords:
    AmericasClinical ResearchClinical TrialsContraceptionContraceptive Agents, Female--side effectsContraceptive Agents, Progestin--side effectsContraceptive Agents--side effectsContraceptive EffectivenessContraceptive Methods--side effectsDepo-provera--side effectsDeveloped CountriesFamily PlanningInjectables--side effectsLiterature ReviewMedroxyprogesterone Acetate--side effectsNorth AmericaNorthern AmericaResearch MethodologyUnited States

    Related Experiment Videos

  • Comparison of DMPA's side effect profile, particularly menstrual changes and weight gain, with other hormonal contraceptives.
  • Analysis of DMPA's suitability for women with contraindications to combined oral contraceptives, such as those with focal migraines or thrombosis risk.

    • Main Results:

    • DMPA demonstrates a very low failure rate, comparable to copper IUDs.
    • Menstrual disturbance and weight gain are the primary potential disadvantages, though rarely require medical intervention and can be managed.
    • DMPA has no significant impact on blood pressure or thrombosis risk, making it a safe alternative for women who cannot use combined oral contraceptives.

    Conclusions:

    • DMPA is a highly effective and advantageous reversible contraceptive method that should be widely available.
    • Comprehensive pre-use counseling is essential to address patient concerns, manage side effects, and ensure informed choices.
    • Accurate and accessible patient information is vital to combat misinformation and improve the public image of DMPA.